Wolverine Stack
The Wolverine Stack combines BPC-157, a synthetic gastric peptide promoting angiogenesis and tissue repair, with TB-500 (thymosin beta-4 fragment), which enhances cell migration and tissue regeneration. Both peptides are studied in preclinical models for their synergistic regenerative and anti-inflammatory potential.
Combines BPC-157 and TB-500 for synergistic tissue repair and recovery. 87.5% improvement in knee pain patients per Lee & Padgett 2021 study.
Mechanism of Action
BPC-157 increases actin production and modulates nitric oxide for vascular effects; TB-500 sequesters actin for cell migration; synergistic enhancement of fibroblast and immune cell movement to injury sites.
Reconstitution Calculator
Safety Profile
Safety Profile: Wolverine Stack
Common Side Effects
- The Wolverine Stack typically combines BPC-157 and TB-500 (thymosin beta-4); side effects are additive from both peptides
- Injection site reactions including pain, redness, swelling, and bruising (subcutaneous or intramuscular administration)
- Mild nausea and headache during initial dosing
- Transient flu-like symptoms (low-grade fever, fatigue, malaise)
- Mild dizziness and lightheadedness
- GI discomfort when BPC-157 is taken orally
Serious Adverse Effects
- Cancer concerns from TB-500: Thymosin beta-4 promotes angiogenesis and cell migration; theoretical risk of promoting existing tumor growth or metastasis
- BPC-157 long-term safety unknown: Despite widespread use, no completed Phase III human clinical trials exist for BPC-157; long-term safety profile is unestablished
- Immune dysregulation: Combined immunomodulatory effects of both peptides may lead to unpredictable immune responses
- Both peptides are research chemicals, not FDA-approved for human use; quality control and purity of sourced products vary widely
- Potential for contamination with endotoxins, heavy metals, or misidentified peptides from unregulated suppliers
Contraindications
- Known or suspected malignancy (TB-500's pro-angiogenic properties may promote tumor growth)
- Known hypersensitivity to BPC-157, thymosin beta-4, or related peptides
- Pregnancy and lactation (no reproductive safety data for either peptide)
- Active systemic infections
- Recent history of cancer (within 5 years) without oncologist clearance
- Concurrent anti-angiogenic cancer therapy (directly opposes TB-500 mechanism)
Drug Interactions
- Anti-angiogenic cancer therapies (bevacizumab, sunitinib): TB-500 directly opposes these drugs' mechanism; strictly contraindicated
- Immunosuppressants: Both peptides may interfere with immunosuppressive therapy
- Growth hormone, IGF-1, and other growth factors: Additive proliferative effects; increased risk of excessive tissue response
- Anticoagulants: BPC-157 may affect platelet function; TB-500 injection may increase bruising
- Corticosteroids: Complex interaction; may partially antagonize peptide effects
Population-Specific Considerations
- Athletes: Both peptides are prohibited by WADA; TB-500 under S2 (peptide hormones/growth factors); BPC-157 under S0 (non-approved substances)
- Elderly: Potentially beneficial for tissue repair and recovery, but cancer risk assessment is critical before use
- Pediatric: No safety data; not recommended
- Post-surgical patients: Some anecdotal use for accelerated recovery, but neither peptide is FDA-approved for this purpose
- Cancer survivors: Avoid due to TB-500's pro-angiogenic properties unless specifically cleared by oncologist
Pharmacokinetic Profile
- Half-life
- Peptide Interactions
Quick Start
- Typical Dose
- BPC-157: 250-500 mcg per dose + TB-500: 2-2.5 mg per dose
- Frequency
- BPC-157: 1-2x daily; TB-500: 2x per week (typically Monday/Thursday or Tuesday/Friday)
- Cycle Length
- 4-8 weeks for injury recovery; shorter for maintenance
- Storage
- Lyophilized powder: room temperature acceptable; Reconstituted: 2-8°C refrigerated for both peptides
Research Indications
Tissue Repair
Both peptides show evidence for accelerated repair; BPC-157 improved Achilles tendon healing in animal models.
BPC-157 demonstrates enhanced muscle regeneration; TB-500 promotes cell migration essential for repair.
Lee & Padgett study showed 87.5% of knee pain patients improved with BPC-157/TB4 combination.
Wound Healing
TB-500 Phase 2 trials showed approximately one month faster healing in ulcer patients.
Anti-Inflammatory
Both peptides modulate inflammatory pathways through different mechanisms.
Research Protocols
subcutaneous Injection
Subcutaneous injection recommended; most studied and effective route.
| Goal | Dose | Frequency | Duration |
|---|---|---|---|
| General Recovery Protocol | BPC-157: 250mcg 2x/day + TB-500: 2mg 2x/week | BPC-157 daily, TB-500 twice weekly | —(Route: SubQ) |
| Intensive Injury Recovery | BPC-157: 500mcg 2x/day + TB-500: 2.5mg 2x/week | BPC-157 daily, TB-500 twice weekly | —(Route: SubQ near injury site) |
| Maintenance/Prevention Protocol | BPC-157: 250mcg 1x/day + TB-500: 2mg 1x/week | BPC-157 daily, TB-500 weekly | —(Route: SubQ) |
Reconstitution Guide (mg vial + mL BAC water)
- Reconstitute each peptide separately
- BPC-157: Add 2mL BAC water to 5mg vial = 250mcg per 0.1mL
- TB-500: Add 2mL BAC water to 5mg vial = 250mcg per 0.1mL
- Inject slowly along vial wall; swirl gently—never shake
- Store reconstituted peptides refrigerated at 2-8°C
- Do NOT mix peptides in same syringe unless pre-made blend
- Use separate injection sites if administering same day
oral
BPC-157 stable in gastric acid; TB-500 oral bioavailability less established.
| Goal | Dose | Frequency | Duration |
|---|---|---|---|
| GI Support Protocol | BPC-157: 500mcg-1mg | Once daily on empty stomach | —(Route: Oral capsule or sublingual) |
Interactions
What to Expect
What to Expect
Possible reduction in acute inflammation and pain at injury sites
Noticeable improvement in recovery between workouts; reduced soreness
Significant improvement in chronic injuries; improved joint comfort
Optimal healing effects; structural improvements in damaged tissues
Benefits may persist as healed tissue maintains integrity
Safety Profile
Common Side Effects
- Not extensively documented in human studies
- Generally well-tolerated in available research
Contraindications
- ANY history of cancer or suspicious growths
- Active malignancy or concurrent chemotherapy
- Pregnancy or breastfeeding
Discontinue If
- Any unusual lumps, growths, or rapid tissue changes
- Severe injection site reactions or infections
- Signs of allergic reaction (rash, swelling, difficulty breathing)
- Unexpected bleeding or bruising
- Persistent headaches or vision changes
- Any symptoms suggesting abnormal growth
Quality Indicators
What to look for
- White or off-white lyophilized powder cake indicating proper freeze-drying
- Crystal clear solution after reconstitution with bacteriostatic water
- Certificate of Analysis with HPLC purity testing (>98%) and mass spectrometry verification
Caution
- Minor clumping acceptable if dissolves completely with gentle swirling
Red flags
- Collapsed, yellowed, or powder stuck to vial sides—may indicate degradation from heat
- Persistent cloudiness or visible particles after reconstitution—indicates contamination or degradation
References (6)
- [1]BPC-157 + TB4 Knee Pain Study (Lee & Padgett) (2021)
- [2]BPC-157 Systematic Review (Vasireddi et al.) (2025)
- [3]Thymosin β4 Clinical Wound Healing (Treadwell et al.) (2012)
- [4]Thymosin β4 Regenerative Properties Review (Goldstein et al.) (2012)
- [5]BPC-157 Achilles Tendon Healing (2003)
- [6]Thymosin β4 Wound Healing Acceleration (1999)
WOGONIN
Wogonin is a natural flavonoid compound extracted from Scutellaria baicalensis (Chinese skullcap) and related species. It functions primarily through anti-infla
XANTHOHUMOL
Xanthohumol is a prenylated flavonoid compound derived from hops (Humulus lupulus) with potent antioxidant, anti-inflammatory, and neuroprotective properties. I